Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction

Cardiovascular Research Group, University of Calgary, Alta, Canada.
New England Journal of Medicine (Impact Factor: 55.87). 06/2001; 344(18):1351-7. DOI: 10.1056/NEJM200105033441802
Source: PubMed


Black patients with heart failure have a poorer prognosis than white patients, a difference that has not been adequately explained. Whether racial differences in the response to drug treatment contribute to differences in outcome is unclear. To address this issue, we pooled and analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD) prevention and treatment trials, two large, randomized trials comparing enalapril with placebo in patients with left ventricular dysfunction.
We used a matched-cohort design in which up to four white patients were matched with each black patient according to trial, treatment assignment, sex, left ventricular ejection fraction, and age. A total of 1196 white patients (580 from the prevention trial and 616 from the treatment trial) were matched with 800 black patients (404 from the prevention trial and 396 from the treatment trial). The average duration of follow-up was 35 months in the prevention trial and 33 months in the treatment trial.
The black patients and the matched white patients had similar demographic and clinical characteristics, but the black patients had higher rates of death from any cause (12.2 vs. 9.7 per 100 person-years) and of hospitalization for heart failure (13.2 vs. 7.7 per 100 person-years). Despite similar doses of drug in the two groups, enalapril therapy, as compared with placebo, was associated with a 44 percent reduction (95 percent confidence interval, 27 to 57 percent) in the risk of hospitalization for heart failure among the white patients (P<0.001) but with no significant reduction among black patients (P=0.74). At one year, enalapril therapy was associated with significant reductions from base line in systolic blood pressure (by a mean [+/-SD] of 5.0+/-17.1 mm Hg) and diastolic blood pressure (3.6+/-10.6 mm Hg) among the white patients, but not among the black patients. No significant change in the risk of death was observed in association with enalapril therapy in either group.
Enalapril therapy is associated with a significant reduction in the risk of hospitalization for heart failure among white patients with left ventricular dysfunction, but not among similar black patients. This finding underscores the need for additional research on the efficacy of therapies for heart failure in black patients.

  • Source
    • "Categorical variables were expressed as percentages. As response to AIAB therapy differs by race, we decided a priori to stratify all analyses by race/ethnicity.[20] Significant (or borderline significant) interactions between AIAB use and race/ethnicity for RV volumes (P = 0.02 for RVEDV and P = 0.16 for RVESV, respectively) supported this approach. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The pulmonary vasculature is an important site of renin-angiotensin metabolism. While angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (collectively AIABs) have a role in left ventricular (LV) disease, the impact of AIABs on right ventricular (RV) function is unknown. AIAB use was determined by medication inventory during the Multi-Ethnic Study of Atherosclerosis baseline examination. RV measures were obtained via cardiac magnetic resonance imaging. The relationship between AIAB use and RV measures was assessed using multivariable linear regression, stratified by race/ethnicity, and adjusted for multiple covariates. AIAB use was associated with lower RV mass (-0.7 g, 95% confidence interval [CI] -1.3 to -0.1, P=0.03) in African Americans (N=1012) after adjustment for multiple covariates including LV mass. Among Caucasians (N=1591), AIAB use was associated with larger RV end-diastolic volume (3.7 mL, 95% CI 0.7-6.8, P=0.02) after adjustment for LV volume. No significant associations were seen between AIAB use and other RV measures or in Hispanic or Chinese American participants. AIAB use was associated with RV morphology in a race-specific and LV-independent manner, suggesting the renin-angiotensin system may play a unique role in RV structure and function. The use of AIABs in those with RV dysfunction warrants further study.
    Full-text · Article · Jul 2012
  • Source
    • "Such research biases in the behavioral and brain sciences are particularly worrisome given the important interplay of culture and genes in the study of population health (Shields et al., 2005; Wang and Sue, 2005). For instance, whereas Ashkenazi Jews have a greater likelihood of Tay-Sachs disease , people from Northern Europe are more likely to develop cystic fibrosis (Exner et al., 2001; Wang and Sue, 2005). Another example of population differences in health as a function of variability in allelic frequency at a specific genetic locus stems from research on the gene CYP2A6, which encodes an enzyme involved in the peripheral metabolism , and nicotine addiction (Shields et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cultural neuroscience is an emerging research discipline that investigates cultural variation in psychological, neural and genomic processes as a means of articulating the bidirectional relationship of these processes and their emergent properties. Research in cultural neuroscience integrates theory and methods from anthropology, cultural psychology, neuroscience and neurogenetics. Here, we review a set of core theoretical and methodological challenges facing researchers when planning and conducting cultural neuroscience studies, and provide suggestions for overcoming these challenges. In particular, we focus on the problems of defining culture and culturally appropriate experimental tasks, comparing neuroimaging data acquired from different populations and scanner sites and identifying functional genetic polymorphisms relevant to culture. Implications of cultural neuroscience research for addressing current issues in population health disparities are discussed. © The Author (2010). Published by Oxford University Press. For Permissions, please email: [email protected] /* */
    Full-text · Article · Jun 2010 · Social Cognitive and Affective Neuroscience
  • Source
    • "The study of ancestry or ethnicity in biological and clinical sciences continues to raise controversy. In May 2001 the New England Journal of Medicine (NEJM) published a landmark study reporting that African-American heart failure patients with left ventricular dysfunction did not benefit from the popular angiotensin-converting enzyme inhibitor drug enalapril, while the same drug reduced the heart failure hospitalization risk of Caucasian patients by 44% [1]. The NEJM report, which eventually paved the road for the US Food and Drug Administration (FDA) approval of BiDil as the first 'ethnic medicine' four years later, was accompanied by two editorials - a rare practice for the NEJM - one heralding it as 'great help to physicians in their attempt to choose the best therapy for heart failure in patients of different races' [2], and the other condemning it and demanding that 'tax-supported trolling of data bases to find racial distinctions in human biology must end' [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Disparities in health outcomes of members of different ancestral or ethnic groups can be observed in both developed and developing countries and continue to be a global concern. Genomic medicine can help toward closing this gap by expanding the knowledge on novel alleles related to disease risk and drug response, their frequencies, and their relation with disease and drug-response phenotypes, in as many countries and ethnic groups as possible. Without such knowledge, genomic medicine cannot deliver upon its promise of contributing to health for all. However, the use of ancestry or ethnicity-related genetic information as a selection criterion for assigning varying levels of access to health care is condemnable. Translational genomic medicine will allow for individualized clinical decision making - doing away with the use of race, ethnicity or ancestry as a proxy.
    Full-text · Article · Mar 2009 · Genome Medicine
Show more